# Oral GLP-1 Pills in 2026: Wegovy Pill and Foundayo — What to Track
Source: https://www.trackpep.com/blog/oral-glp-1-pills-what-to-track
> Educational information only. Not medical advice, and not a dosing recommendation. TrackPep records what you enter; it never calculates, converts or decides a dose for you. Talk to a licensed clinician.
The Wegovy pill and Lilly's Foundayo (orforglipron) are daily tablets, not weekly pens. Here is what has been reported so far, and what a good log looks like when the routine is every morning instead of every week.
## Short answer
The FDA has approved two oral GLP-1 pills for weight management: Novo Nordisk's Wegovy pill (December 2025) and Lilly's Foundayo, or orforglipron (April 2026). Because they are taken daily, your log shifts from weekly injection entries to daily timing, food and water timing per the label, side effects, missed days, weight trend and monthly cost.
## The short version
Two once-daily GLP-1 tablets are now FDA approved for weight management in the United States. Novo Nordisk announced approval of the **Wegovy pill** (oral semaglutide 25 mg) on 22 December 2025, and trade press reported that Lilly's **Foundayo** (orforglipron) was approved on 1 April 2026 for adults with obesity. Both are prescription medicines, and both change what a useful log looks like: the weekly injection ritual becomes a daily habit with its own timing rules.
**This is news and a tracking guide, not medical advice.** TrackPep does not sell, recommend, or help you obtain any medication, and it never calculates or suggests a dose. Everything about how to take a pill comes from the product label and your prescriber. Facts below are attributed and dated: **as of October 2026, check the manufacturer's page** for the current label and price.
## What has been reported so far
We only state what we could confirm in published coverage, and we name the source.
- **Wegovy pill.** According to Novo Nordisk, it is a once-daily 25 mg semaglutide tablet approved on 22 December 2025, the first oral GLP-1 for weight loss. The company said the 1.5 mg starting tablet became available on 5 January 2026 at a self-pay price of $149 a month. Higher tiers cost more; our [Wegovy pill vs injection cost](/blog/wegovy-pill-vs-injection-cost) post lists the published ladder.
- **Trial results for the Wegovy pill.** In the OASIS 4 trial, Novo Nordisk reported weight loss of about 17% if all patients stayed on treatment and about 14% when everyone was analysed regardless of adherence, against roughly 3% and 2% for placebo. Common side effects were described as similar to the Wegovy injection: nausea, diarrhea and vomiting.
- **Foundayo (orforglipron).** Trade press reported FDA approval on 1 April 2026 under the Commissioner's National Priority Voucher program, available first through LillyDirect. According to coverage of Lilly's announcement, cash prices range from $149 to $349 a month depending on dose, insured patients may pay from $25 with a Lilly savings card, and Reuters-sourced reporting said most patients were expected to pay around $349, falling to about $299 with refill incentives.
- **Foundayo trial results.** In the ATTAIN-1 trial, adults on the highest dose lost an average of 12.4% of body weight versus 0.9% on placebo among those who stayed on treatment, and 11.1% versus 2.1% counting all participants, as summarised in press coverage.
What we are leaving out: head-to-head claims, discontinuation percentages we could not verify in a primary source, and any availability outside the United States. Trial numbers come from different trials with different designs, so please do not read them as a scoreboard between the two drugs.
## Why a pill needs a different log
A weekly pen is easy to log because the event is rare. You inject once, write down the site and the day, and then spend six days noticing how you feel. A daily pill flips this: the event is frequent and small, and the information lives in the pattern.
| | Weekly injection | Daily pill |
|---|---|---|
| Entries that matter | One per week | One per day |
| Timing question | Which day of the week | What time of day, relative to food and water |
| Rules to follow | Site rotation, storage | The label's rules on empty stomach, water and waiting time |
| Typical miss | A whole week slips | A single day slips, easy to forget |
| Side-effect pattern | Often tied to the days after the injection | Can be daily, so link to the time you took it |
| Cost view | Price of a pen, spread over weeks | Price of a month, divided by days |
| What the log shows | Gaps between doses | Streaks, consistency, time drift |
The table is about what you record, not about how much to take. The amount, the schedule and any changes are decisions for you and your prescriber.
## What to log every day
Keep it light, because anything that takes more than ten seconds will be skipped by day nine.
### 1. The time you took it
One tap, ideally at the moment you swallow it. Over a few weeks this reveals drift: a pill meant for early morning that slowly becomes mid-morning, or weekends that look different from weekdays. If the label ties the pill to an empty stomach, the time is the anchor for everything else.
### 2. Food and water timing, as the label requires
Oral GLP-1 tablets come with specific administration instructions, which can include fasting, how much water to use and how long to wait before eating or drinking anything else. We are not going to paraphrase those rules, because they differ by product and the label is the authority. Read the current prescribing information on the manufacturer's site, ask your pharmacist to walk you through it, and then log a simple yes or no: did I follow the instructions today? A "no" with a short note about why is more useful to your prescriber than a perfect streak that hides the hard mornings.
### 3. Gastrointestinal effects
Nausea, diarrhea, vomiting, constipation and reflux are the effects the trials and labels talk about most. Record severity on a three-step scale (mild, moderate, severe), the time it started relative to the pill and to meals, and anything you changed. Our [GLP-1 side effects tracker guide](/blog/glp-1-side-effects-tracker) covers the fields in more detail, and the [hydration tracking post](/blog/hydration-tracking-glp1) explains why fluids matter when your stomach is unsettled. If symptoms are severe or you cannot keep fluids down, contact your prescriber instead of waiting for the next appointment.
### 4. Missed or late days
Log a miss as a miss. Do not backfill it, and do not guess what to do next; the label and your prescriber decide what happens after a missed tablet. What the log can do is show whether misses cluster on travel days, busy mornings or after a night of bad sleep, which is exactly the information that makes a conversation with your prescriber concrete.
### 5. Weight trend, not weight number
Weigh at a consistent time and let the app show the trend line rather than reacting to a single morning. The [weight tracking on GLP-1 guide](/blog/weight-tracking-on-glp-1) explains why a seven-day average is calmer than the daily number. The trial figures above are averages across groups; your own curve will look different, and that is normal.
### 6. Appetite, energy and anything else you notice
A single line is enough. Hunger, fullness, energy, sleep. Patterns across weeks are the point.
## Tracking the cost per month
Cash prices are the most volatile part of this story, so record what you actually pay rather than what a headline says.
| What to log | Why |
|---|---|
| Amount paid at the pharmacy | The real number, after coupons |
| Where you filled it | Pharmacy, telehealth platform or manufacturer direct program |
| Coupon or savings card used | Offers have end dates |
| Insurance status that month | Coverage can change in January |
| Fill date and days covered | Shows whether you are paying for days you did not use |
Divide the month's payment by the days covered and you have a daily figure you can compare with a weekly pen. Our post on [how to track GLP-1 cost per dose](/blog/how-to-track-glp-1-cost-per-dose) walks through the bookkeeping, and the [GLP-1 cost guide for 2026](/blog/glp-1-cost-guide-2026) and [semaglutide cost in 2026](/blog/semaglutide-cost-2026) give the wider price context. If you are comparing brand products with compounded alternatives, read [compounded vs brand GLP-1: what changed in 2026](/blog/compounded-vs-brand-glp-1-what-changed-2026) first.
One reported detail worth writing down: the lowest self-pay prices quoted for both pills applied to starting tiers, and higher tiers cost more. Whatever tier you are prescribed is a clinical decision, so your cost log should simply follow the tier you are on and the date it changed.
## Questions to bring to your prescriber
A log is mostly a way to arrive at an appointment with better questions. Here are some to start from:
1. Which form fits my situation, a daily tablet or a weekly pen, and what are the trade-offs for me?
2. What exactly does the label require around food, water and timing, and what should I do on a day I get it wrong?
3. Which side effects should make me call you immediately, rather than wait it out?
4. What happens if I miss a day, or several?
5. How will we judge whether it is working, and when do we review that?
6. What will I pay each month, what happens if my insurance or the manufacturer's offer changes, and is there a lower-cost option you would consider?
7. Which medicines and supplements I already take could interact, and does the pill's timing rule affect when I take them?
Bring the last two to four weeks of your log. A chart of daily timing and symptoms beats memory.
## Where this fits in your tracking setup
If you already track a weekly semaglutide or tirzepatide pen, nothing about your history needs to be thrown away when you switch forms. Keep one timeline, note the date the form changed, and let weight trend, symptoms and cost carry across. The [GLP-1 tracker](/glp-1-tracker), [semaglutide tracker](/semaglutide-tracker) and [tirzepatide tracker](/tirzepatide-tracker) pages show how a continuous log looks. In TrackPep you can record daily entries, side effects, weight and spending in one place, stored privately on your account; it logs what you enter and does not tell you what to take.
## A note on what we do not know
Real-world data on these tablets is still young. Prices, savings cards and pharmacy availability have moved repeatedly since launch, the labels can be updated, and anything we have reported here comes from press coverage and company announcements rather than from our own verification. That is why we recommend the same habit for every claim in this space: note the date, note the source, and check the manufacturer's page before you decide anything.
## Related reading
- [Wegovy pill vs injection cost](/blog/wegovy-pill-vs-injection-cost)
- [GLP-1 side effects tracker](/blog/glp-1-side-effects-tracker)
- [Weight tracking on GLP-1](/blog/weight-tracking-on-glp-1)
- [Compounded vs brand GLP-1: what changed in 2026](/blog/compounded-vs-brand-glp-1-what-changed-2026)
## Frequently asked questions
### Which oral GLP-1 pills are FDA approved for weight loss?
According to Novo Nordisk, the FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg) on 22 December 2025. Lilly's Foundayo (orforglipron) was reported as approved on 1 April 2026. Check each manufacturer's page for the current label.
### What should I log differently with a daily pill than with a weekly injection?
Log the time you took it each day, when you last ate or drank relative to the label's instructions, any missed days, and daily gastrointestinal effects. A weekly pen needs one entry a week; a pill needs a habit of seven.
### How much do the pills cost without insurance?
As reported in the US, Novo Nordisk lists the Wegovy pill starting dose at $149 a month self-pay, and Lilly said Foundayo cash prices range from $149 to $349 a month depending on dose. These are US figures as of October 2026 and change often.
### Are these pills available outside the United States?
The approvals and prices discussed here are US ones. Availability, approval status and pricing differ by country, so ask your prescriber or pharmacist what applies where you live.
## Sources
- [Novo Nordisk: Wegovy pill FDA approval announcement (22 Dec 2025)](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472)
- [Fierce Pharma: Lilly answers Novo's GLP-1 pill with highly anticipated FDA nod for Foundayo](https://www.fiercepharma.com/pharma/lilly-answers-novos-glp-1-pill-highly-anticipated-fda-nod-foundayo)
- [Benefits and Pensions Monitor: New lower-priced rival GLP-1 pill wins FDA approval](https://www.benefitsandpensionsmonitor.com/news/industry-news/new-lower-priced-rival-glp1-pill-wins-fda-approval/393321)
- [Novo Nordisk: Wegovy pill now broadly available across America (Barchart)](https://www.barchart.com/story/news/36883439/novo-nordisk-s-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america)
By TrackPep Team.